The UK and US have agreed to a important trade agreement that will maintain no import taxes on UK pharmaceutical products entering the US market.
The Terms of the Pact
As part of the deal, the UK has pledged to raise expenditure on pharmaceuticals through the NHS. This commitment guarantees that duties on these key exports will be held at nothing for a timeframe of 36 months.
This development comes after recent statements to hike import taxes on branded drug imports, with potential rates floated reaching double the cost.
"This deal between the United Kingdom strengthens the worldwide climate for new treatments and establishes much-needed fairness to U.S.–U.K. medicine commerce," a statement declared.
Trade Impact
Pharmaceuticals are one of the Britain's most significant exports to the America, which is by far the primary market for leading companies like GSK and AstraZeneca.
Export figures reveal that in the 12 months leading up to the third quarter, the UK exported medicines worth over eleven billion pounds to the US. This figure made up 17.4% of all goods exports in that period.
"This agreement protects jobs, boosts funding and paves the way for the UK to establish itself as a international leader for medical research," a government official remarked.
Detailed UK Commitments
The pact includes several key changes from the United Kingdom:
- Revised Affordability Limit: The UK will lift the price threshold at which it considers new medicines to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a goal to increase overall health service expenditure on drugs from 0.3% of GDP to 0.6% over the next decade.
- Refund Ceiling: The percentage pharmaceutical firms must return to the NHS to control costs will be restricted at 15%. Previously, rebates topped 20%.
Broader Context
This agreement takes place against a ongoing row between the drug companies and the UK government over drug pricing and NHS adoption.
These tensions were heightened by claims that American consumers were charged several times more for the same drugs than consumers in the other developed nations.
In recent months, several major pharmaceutical investments in the UK have been paused or scrapped, while multi-billion-dollar funding commitments have been announced toward US facilities.
A senior figure acknowledged that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had shrunk as a proportion of its total funding over the past decade.
